



US009439906B2

(12) **United States Patent**  
**Vermeulen et al.**

(10) **Patent No.:** **US 9,439,906 B2**  
(45) **Date of Patent:** **Sep. 13, 2016**

(54) **DOSING REGIMEN ASSOCIATED WITH  
LONG ACTING INJECTABLE  
PALIPERIDONE ESTERS**

(75) Inventors: **An Vermeulen**, Beerse (BE); **Alfons Wouters**, Beerse (BE)

(73) Assignee: **Janssen Pharmaceutica NV** (BE)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 770 days.

(21) Appl. No.: **12/337,144**

(22) Filed: **Dec. 17, 2008**

(65) **Prior Publication Data**

US 2009/0163519 A1 Jun. 25, 2009

**Related U.S. Application Data**

(60) Provisional application No. 61/014,918, filed on Dec. 19, 2007, provisional application No. 61/120,276, filed on Dec. 5, 2008.

(51) **Int. Cl.**

**C07D 471/04** (2006.01)  
**A61K 31/445** (2006.01)  
**A61K 31/41** (2006.01)  
**A61K 31/42** (2006.01)  
**A61K 31/519** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 31/519** (2013.01)

(58) **Field of Classification Search**

CPC . A61K 31/519; A61K 9/0019; A61K 9/0024  
USPC ..... 514/257, 323, 360, 379  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,804,663 A 2/1989 Kennis et al.  
5,158,952 A 10/1992 Janssen et al.  
5,254,556 A 10/1993 Janssen et al.  
5,453,425 A 9/1995 Francois et al.  
5,612,346 A 3/1997 Mesens et al.  
6,077,843 A 6/2000 François et al.  
6,555,544 B2 4/2003 François et al.  
6,577,545 B2 6/2003 Kim et al.  
2002/0082245 A1 6/2002 Yelle  
2003/0157180 A1 8/2003 Francois et al.  
2007/0197591 A1 8/2007 Boom et al.  
2009/0163519 A1 6/2009 Vermeulen et al.  
2011/0105536 A1 5/2011 Lewyn-Briscoe et al.  
2012/0263795 A1 10/2012 Francois et al.

**FOREIGN PATENT DOCUMENTS**

WO 2004/010981 2/2004  
WO WO 2006/114384 11/2006  
WO 2008/021342 2/2008  
WO 2009/025859 2/2009  
WO 2009/047499 4/2009  
WO 2009/080651 7/2009  
WO 2011/053829 5/2011

**OTHER PUBLICATIONS**

Diagnosed Schizophrenia. Poster No. NR6-21 at the 163rd Annual Meeting of the American Psychiatric Association (APA), New Orleans, Louisiana, USA, May 22-26, 2010.

Alphs L, Haskins, Bossie C, Sliwa JK, Gopal S, Hough D, Davis J Long-term Metabolic Outcomes With Paliperidone Palmitate, A Once-Monthly Long-Acting Injectable Antipsychotic Agent, in the Treatment of Subjects With Schizophrenia. Poster No. 204 at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, USA, December 6-10, 2009.

Cleton A, Rossenu S, Crauwels H, Berwaerts J, Hough D, Gopal S, Eerdeken M, Vandebosch A, Rosso Fernandez C Assessment of the Dose Proportionality of Paliperidone Palmitate 25, 50, 100 and 150 mg eq., A New Long-Acting Injectable Antipsychotic, Following Administration in the Deltoid or Gluteal Muscles. Poster at the 2008 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), Orlando, Florida, USA, Apr. 2-5, 2008.

Coppola D, Liu Y, Gopal S, Remmerie B, Samtani M, Pandina G, Hough D, Nuamah I, Sulaiman A Long-Term Safety, Tolerability and Pharmacokinetics of Paliperidone Palmitate 234 mg (150 mg eq.), The Highest Marketed Dose: A One-Year Open-Label Study in Patients With Schizophrenia. Poster No. PI-49 at the 2010 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), Atlanta, Georgia, USA, Mar. 17-20, 2010.

Gopal S, Berwaerts J, Nuamah I, Akhras K, Coppola D, Daly E, Hough DW, Palumbo JM Efficacy and Safety of Long-Acting Injectable Paliperidone Palmitate Relative to Long-Acting Haloperidol, Bromperidol and Fluphenazine Decanoate for Long-Term Treatment in Patients With Schizophrenia Using Number Needed to Treat and Number Needed to Harm. Poster at the 65th Annual Convention and Scientific Program of the Society of Biological Psychiatry (SOBP), New Orleans, Louisiana, USA, May 20-22, 2010.

Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L, Practical Guidance for Dosing and Switching Paliperidone Palmitate Treatment in Patients with Schizophrenia, Current Medical Research and Opinion 26 (2), p. 377-387, 2010.

Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdeken MH, Brown DW, Efficacy and Safety of Paliperidone Palmitate in Adult Patients with Acutely Symptomatic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study, International Clinical Psychopharmacology, pp. 247-256 (2010).

Gopal S, Lindenmayer JP, Hough D, Melkote R, Lim P, Eerdeken M, Safety and Tolerability of the Investigational Antipsychotic Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Patients with Schizophrenia, 63rd Annual Convention and Scientific Program of the Society of Biological Psychiatry (SOBP), Washington, DC, USA, May 1-3, 2008, Biological Psychiatry 63 (7, Suppl. 7), p. 285S, 2008.

Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdeken M Long-Term Efficacy, Safety and Tolerability of Paliperidone Palmitate in Patients with Schizophrenia. Poster No. 20 at the 12th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP), Jacksonville, Florida, Apr. 19-22, 2009.

(Continued)

*Primary Examiner* — Sreeni Padmanabhan

*Assistant Examiner* — Jody Karol

(57) **ABSTRACT**

The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.

(56)

## References Cited

## OTHER PUBLICATIONS

Haskins JT, Sliwa JK, Ma YW, Pandina GJ, Palumbo J Efficacy and Safety of 234 mg Initiation Dose and 3-Fixed Maintenance Doses of Paliperidone Palmitate—A Once-Monthly Injectable Atypical Antipsychotic. Poster No. 123 at the 22nd US Psychiatric and Mental Health Congress (USPMHC), Las Vegas, Nevada, USA, Nov. 2-5, 2009.

Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdeken M Paliperidone Palmitate, an Atypical Injectable Antipsychotic, In Prevention of Symptom Recurrence in Patients with Schizophrenia: A Randomized, Double-Blind, Placebo Controlled Study. Poster at the 63rd Annual Convention and Scientific Program of the Society of Biological Psychiatry (SOBP), Washington, DC, USA, May 1-3, 2008.

Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdeken M, Paliperidone Palmitate in Prevention of Symptom Recurrence in Patients with Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study, 161st Meeting of the American Psychiatric Association (APA), Washington, DC, USA, May 3-8, 2008, Proceedings/AbstractBook, p. 173, No. NR4-029, 2008.

Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdeken M, Safety and Tolerability of Deltoid and Gluteal Injections of Paliperidone Palmitate in Schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry 33 (6), p. 1022-1031, 2009.

Kozma C, Dirani R, Nicholl D, Akhras K Evaluation of the Relationships Among Change in Function, Symptoms, and Duration of Schizophrenia. Poster No. NR6-4 at the 163rd Annual Meeting of the American Psychiatric Association (APA), New Orleans, Louisiana, USA, May 22-26, 2010.

Kramer M, Litman R, Hough D, Lane R, Lim P, Eerdeken M A 9-Week, Placebo-Controlled Study in Schizophrenia Patients: Efficacy and Safety of the Long-Acting Injectable Agent, Paliperidone Palmitate. Poster No. 4-072 at the 161st Meeting of the American Psychiatric Association (APA), Washington, DC, USA, May 3-8, 2008.

Kramer M, Litman R, Lane R, Lim P, Hough D, Palumbo J, Eerdeken M Efficacy and Tolerability of Two Fixed Dosages of Paliperidone Palmitate in the Treatment of Schizophrenia: Results of a 9-Week Placebo-Controlled Trial. Poster at the 20th US Psychiatric and Mental Health Congress (USPMHC), Orlando, Florida, USA, Oct. 11-14, 2007.

Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G A Randomized, Double-Blind, Comparative Study of Flexible Doses of Paliperidone Palmitate and Risperidone Long-Acting Therapy in Patients with Schizophrenia. Poster at the 48th Annual Meeting of the American College Neuropsychopharmacology (ACNP), Hollywood, Florida, USA, Dec. 6-10, 2009.

Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Kusumakar V, Yuen E, Palumbo J A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Paliperidone Palmitate in Adults with an Acute Exacerbation of Schizophrenia. Poster at the 12th International Congress on Schizophrenia Research (ICOSR), San Diego, California, USA, Mar. 28-Apr. 1, 2009.

Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Kusumakar V, Yuen E, Palumbo J A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Paliperidone Palmitate in Adults with an Acute Exacerbation of Schizophrenia. Poster at the 12th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP), Jacksonville, Florida, Apr. 19-22, 2009.

Samtani MN, Gopal S, Kern Sliwa J, Haskins JT, Alphas L, Stuyckens K, Vermeulen A Management of Missed Paliperidone Palmitate Doses Based on Pharmacokinetic Modeling and Simulation. Poster at the 49th Annual Meeting of the New Clinical Drug

Samtani MN, Gopal S, Kern Sliwa J, Haskins JT, Alphas L, Stuyckens K, Vermeulen A, Switching to Paliperidone Palmitate From Other Antipsychotics: Guidance Based on Pharmacokinetic Modeling and Simulation, 49th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health (NIMH), Hollywood, Florida, USA, Jun. 29-Jul. 2, 2009, Proceedings/AbstractBook, p. 68, 2009.

Samtani MN, Gopal S, Kern Sliwa J, Haskins T, Alphas L, Stuyckens K, Vermeulen A Paliperidone Palmitate Dosing in Special Patient Populations Including the Elderly and Those With Renal Impairment or Differing Body Mass Index: Guidance Based on Pharmacokinetic Modeling and Simulation. Poster at the American Conference on Pharmacometrics, Mashantucket, Connecticut, USA, Oct. 4-7, 2009.

Samtani MN, Haskins JT, Alphas L, Sliwa JK, Stuyckens K, Herben V, Vermeulen A Maintenance Dosing of Once-Monthly (4-Weekly) Paliperidone Palmitate in Schizophrenia: Pharmacokinetic Rationale Based on Population Simulations. Poster No. 21 at the 12th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP), Jacksonville, Florida, Apr. 19-22, 2009.

Samtani MN, Haskins JT, Gopal S, Sliwa JK, Alphas L, Stuyckens K, Vermeulen A Dosing Information for Paliperidone Palmitate—A Once-Monthly Injectable Atypical Antipsychotic—Based on Population Pharmacokinetic Analysis. Poster No. 310 at the 22nd US Psychiatric and Mental Health Congress (USPMHC), Las Vegas, Nevada, USA, Nov. 2-5, 2009.

Samtani MN, Sliwa JK, Haskins JT, Alphas L, Stuyckens K, Herben V, Vermeulen A Initiation Dosing of Deltoid Intramuscular Paliperidone Palmitate in Schizophrenia: Pharmacokinetic Rationale Based on Modeling and Simulation. Poster No. 19 at the 12th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP), Jacksonville, Florida, Apr. 19-22, 2009.

Samtani MN, Vermeulen A, Stuyckens K, Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia A Novel Once-Monthly, Long-Acting Formulation of an Atypical Antipsychotic, Clinical Pharmacokinetics 48 (9), p. 585-600, 2009.

Sikirica M, Crivera C, Dirani R, Cost-Effectiveness of Paliperidone Palmitate Versus Oral Atypicals in the US. Poster No. NR6-5 at the 163rd Annual Meeting of the American Psychiatric Association (APA), New Orleans, Louisiana, USA, May 22-26, 2010.

Turner N, Bossie CA, Haskins JT, Kern Sliwa J, Ma YW, Alphas L Effects of Paliperidone Palmitate in Acutely ill Subjects With a Marked to Severe Exacerbation of Schizophrenia. Poster No. NR6-26 at the 163rd Annual Meeting of the American Psychiatric Association (APA), New Orleans, Louisiana, USA, May 22-26, 2010.

Alphas et al., "Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases", Current Drug Safety, 2011, 6, 43-45.

Alphas et al., "Paliperidone Palmitate Versus Risperidone Long-Acting Therapy in Markedly to Severely ill Subjects With Schizophrenia", Poster presented at the 23rd Annual US Psychiatric and Mental Health Congress; Supported by Ortho-McNeil Janssen Scientific Affairs, LLC Nov. 18-21, 2010; Orlando, FL, USA.

Alphas et al., "Tolerability of Paliperidone Palmitate Initiation Doses in Subjects with Recently Diagnosed Schizophrenia", Poster hand-out presented at The Scientific Program of XXVII CINP Congress, Hong Kong, Jun. 6-10, 2010.

Alphas et al., "Tolerability of Paliperidone Palmitate Initiation Doses in Subjects with Recently Diagnosed Schizophrenia", Poster presented at The Scientific Program of XXVII CINP Congress, Hong Kong, Jun. 6-10, 2010.

Cleton et al., Clinical Pharmacology & Therapeutics, Mosby-Year Book, St. Louis, MO, US, vol. 81, No. Suppl. 1, p. S63 (2007).

Cockcroft et al., Prediction of creatinine clearance from serum creatinine, Nephron, 16:31-41, 1976.

Fleischhacker, W. Wolfgang et al., "A randomized trial of paliperidone palmitate and risperidone long-acting injectable in

(56)

## References Cited

## OTHER PUBLICATIONS

- Gopal et al., "A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia", *J Psychopharmacol*. 2010; First View: 1-13.
- Gopal et al., "Dosing Information for Paliperidone Palmitate—A Once-Monthly Injectable Atypical Antipsychotic—Based on Population Pharmacokinetic Analysis", Poster presented at The Scientific Program of XXVII CINP Congress, Hong Kong. Jun. 6-10, 2010.
- Gopal et al., "Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study", *International Clinical Psychopharmacology* 2010, vol. 25 No. 5, pp. 247-256.
- Gopal et al., Risk of Cardiovascular Morbidity and Sudden Death with Risperidone and Paliperidone Treatment: Analysis of 64 Randomized, Double-Blind Trials, NR 10-24 Presented at the 164th Annual Meeting—American Psychiatric Association, May 14-18, 2011; Honolulu, Hawaii.
- Hough et al., "Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study", *Schizophrenia Research* 116 (2010) 107-117.
- Hough et al., "Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia", *Prog Neuropsychopharmacol Biol Psychiatry*. 2009;33:1022-1031.
- Li et al., "A Comparative Randomized, Open-label, Rater-blinded Study of Paliperidone Palmitate and Risperidone Long-Acting Injectable Therapy in Patients with Schizophrenia", Poster No. P-11-005 presented at the XXVII CINP Congress, Jun. 6-10, 2010; Hong Kong.
- Nasrallah et al., "A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia", *Neuropsychopharmacology* (2010) 35, 2072-2082.
- Pandina et al., "A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia", *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 2011;35:218-226.
- Pandina et al., "A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia", *J Clin Psychopharmacol*. 2010;30:235-244.
- Revill et al., *Drugs of the Future*, Prous Science, ES, vol. 31, No. 7, pp. 579-584 (2006).
- Samtani et al., "Dosing and Switching Strategies for Paliperidone Palmitate", *CNS Drugs* 2011; 25(10): 829-845.
- Samtani et al., "Expansion of Paliperidone Palmitate Day 8 Dose Window from  $\pm 2$  Days to  $\pm 4$  Days: Model-Based Pharmacokinetic Simulation and Safety Data", Poster presented at the 24th Annual U.S. Psychiatric and Mental Health Congress Meeting, Nov. 7-10, 2011, Las Vegas, Nevada.
- Samtani et al., "Expansion of Paliperidone Palmitate Day 8 Dose Window from  $\pm 2$  Days to  $\pm 4$  Days: Model-Based Pharmacokinetic Simulation and Safety Data", Poster handout presented at the 24th Annual U.S. Psychiatric and Mental Health Congress Meeting, Nov. 7-10, 2011, Las Vegas, Nevada.
- Samtani et al., "Switching to Paliperidone Palmitate<sup>1,2</sup> from Other Depot Antipsychotics Guidance Based on Pharmacokinetic Simulations", Population Approach Group in Europe, Applications—CNS (Group IV) Abstr 1839, Berlin, Germany. Jun. 8-11, 2010.
- Samtani, Mahesh N., "Use of Model Based Simulations to Support the Paliperidone Palmitate Label", AAPS Workshop on Facilitating Oral Product Development and Reducing Regulatory Burden through Novel Approaches to Assess Bioavailability/Bioequivalence, Oct. 22-23, 2011, Washington.
- Sheehan et al., "The Management of Antipsychotic Treatment Discontinuation and Interruptions Using Model-Based Simulations", Poster presented at the 51st Annual NCDEU New Research
- Sliwa et al., "Tolerability and Efficacy of Paliperidone Palmitate vs Risperidone Long-acting Injection in Subjects with Recently Diagnosed Schizophrenia", Presented at the 13th International Congress on Schizophrenia Research; Apr. 2-6, 2011; Colorado Springs, Colorado, USA.
- Alen et al., *Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems*, 8<sup>th</sup> Edition, 2005; pp. 260-263, 652-653, 682.
- Guidance Document: Patented Medicines (Notice of Compliance) Regulations, Health Canada, Nov. 12, 2010.
- New Drug Application (NDA) dated Oct. 25, 2007 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Invega Sustenna (paliperidone palmitate) 39mg, 78mg, 117mg, 156mg, and 234 mg extended-release injectable suspension, date of letter is Jul. 31, 2009.
- Supplemental New Drug Application (sNDA) dated Mar. 14, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, 39 mg, 78 mg, 117 mg, 156 mg, and 234 mg.
- Alphs et al. *Annals of General Psychiatry* 2011, 10:12.
- Altamura et al., *Intramuscular preparations of antipsychotics: uses and relevance in clinical practice*. *Drugs*. 2003; 63(5): 493-512.
- Berwaerts et al., *Journal of Affective Disorders* 138 (2012) 247-258.
- Canuso et al. 2010, *Expert Opinion Pharmacother.*, vol. 11 (15), pp. 2557-2567.
- Cleton et al., Assessment of the Dose Proportionality of Paliperidone Palmitate 25, 50, 100 and 150 MG EQ., A New Long-Acting Injectable Antipsychotic Following Administration in the Deltoid or Gluteal Muscles, PI-74, *Clinical Pharmacology & Therapeutics*, vol. 83, Supplement 1, Mar. 2008, S31.
- Ereshefsky L., *Pharmacokinetics and drug interactions: update for new antipsychotics*. *J Clin Psychiatry*. 1996;57 Suppl 11:12-25.
- Gefvert et al. *Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia*. *Int J Neuropsychopharmacol*. 2005; 8(1): 27-36.
- Kane et al., *Guidelines for depot antipsychotic treatment in schizophrenia*. *European Neuropsychopharmacology Consensus Conference in Siena, Italy*. *Eur Neuropsychopharmacol*. 1998; 8(1): 55-66.
- Levron et al., *Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics*. *Encephale*. 1987; 13(2): 83-7 [see English Summary as provided].
- Markowitz et al., "Benefit-Risk Assessment of Maintenance Therapy in Schizophrenia Comparing Long-Acting Injectable (LAI) Paliperidone Palmitate with Paliperidone ER", Presented at the 164th Annual Meeting of the American Psychiatric Association, May 14-18, 2011, Honolulu, HI, USA.
- Mauri et al., *Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response*. *Clin Pharmacokinet*. 2007;46(5):359-88.
- Pandina et al., *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 35 (2011) 218-226.
- Sheehan et al., *Comparison of the Peak-to-trough Fluctuation in Plasma Concentration of Long-acting Injectable Antipsychotics and Their Oral Equivalents*, *Innov Clin Neurosci*. 2012;9(7-8):17-23.
- Vermeir et al., *Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans*. *Drug Metab Dispos*. Apr. 2008;36(4):769-79.
- Lewyn-Briscoe et al., U.S. Appl. No. 13/903,638.
- International Search Report Re: International Application No. PCT/US2010/054807 dated Jan. 11, 2011.
- Office Action mailed Feb. 28, 2013 in U.S. Appl. No. 12/916,910.
- Kazuo Yamada et al., *Future Potentiality of Pharmacotherapy for Schizophrenia in Acute Phase*, *Clinical Psychopharmacology*, vol. 8, No. 10 (2005), pp. 1563-1568.
- Takashi Yoshio, *Sustained-release Antipsychotic Drugs (depot drugs)*, *Psychiatric Nursing*, vol. 33, No. 4 (2006), pp. 64-67.
- Gibaldi's Drug Delivery Systems in Pharmaceutical Care*, edited by Mary Lee, Archana Desai, American Society of Health-System Pharmacists, Inc. (2007), pp. 103-108.

(56)

**References Cited**

## OTHER PUBLICATIONS

Australian Patent Opposition for AU Patent Appl No. 2008340101 dated May 20, 2015.

Statement of Grounds and Particulars dated Aug. 19, 2015 re: Australian Patent Opposition for AU Patent Appl No. 2008340101. Cleton A, Rossenu S, Crauwels H, et al. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. *J Clin Pharmacol.* 2014;54(9):1048-1057.

Cleton A, Rossenu S, Hough D, Crauwels H, Vandebosch A, Berwaerts J, Eerdeken M, Francetic, I. "Evaluation of the pharmacokinetic profile of gluteal versus deltoid intramuscular injections of paliperidone palmitate 100 mg equivalent in patients with schizophrenia" *Clin.Pharmacol. Therapeutics.* Published Mar. 2008.

Cockshott WP, Thompson GT, Howlett LJ, Seeley ET. Intramuscular or intralipomatous injections? *N Engl J Med.* 1982;307(6):356-358.

Haramati N, Lorans R, Lutwin M, Kaleya RN. Injection granulomas. Intramuscle or intrafat? *Arch Fam Med.* 1994;3(2):146-148.

Janicak, P. G. and Winans, E. A. "Paliperidone ER: a review of the clinical trial data" *Neuropsychiatr. Dis. Treat.* Dec. 3, 2007(6): 869-897 Published Jan. 15, 2008.

Rosen, H, and Aribat, T. "The rise and rise of drug delivery" *Nat. Rev. Drug Discov.* May 4, 2005(5): 381-5.

Rossenu S, Cleton A, Hough D, et al. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. *Clinical Pharmacology in Drug Development.* 2015;4(4):270-278.

Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. *Clin Pharmacokinet.* 2009;48(9):585-600.

Synopsis of the Phase III clinical study described at Example 8 of the opposed application accessed at <http://yoda.yale.edu/sites/default/files/nct00590577.pdf> on Aug. 17, 2015, Issue Date: Sep. 12, 2008.

Yin J, Collier AC, Barr AM, Honer WG, Procyshyn RM. Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent? *J Clin Psychopharmacol.* 2015;35(4):447-449.


Kreyenbuhl, et al., "Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia", *Psychiatr Serv.*, Jul. 2007, pp. 983-990, vol. 58(7).

Third Party Observations dated Jan. 28, 2016 filed during prosecution of EP Application No. 10773821.3.

Office Action mailed Mar. 24, 2015 in U.S. Appl. No. 13/903,638. Final Office Action mailed Oct. 22, 2015 in U.S. Appl. No. 13/903,638.

Cirincione, et al., "Population pharmacokinetics of paliperidone ER in healthy subjects and patients with schizophrenia", *clinical Pharmacology & Therapeutics*, vol. 81, Issue Supplement SI, P. S19 (published in Mar. 2007).

**FIG. 1**



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.